2. Evading Growth Suppressors Cyclin-Dependent Kinases Palbociclib CDK-4/6 All University of Pennsylvania Palbociclib CDK-4/6 All Paclitaxel University of Pennsylvania Palbociclib CDK-4/6 Hormone+_HER2- Fulvestrant Pfizer Active, not recruiting Palbociclib CDK-4/7 Hormone+_HER2- Letrozole Pfizer Active, not recruiting LY2835219 CDK-4/6 All Eli Lilly LY2835219 CDK-4/6 Hormone+_HER2- Standard Hermone Therapy or everoli- mus/ exemestane Eli Lilly LEE011 CDK-4/6 Hormone+_HER2- Exemestane and everolimus Novartis LEE011 CDK-4/6 Hormone+_HER2- Letrozole Novartis LEE011 and BYL719 CDK-4/6 & PI3 Hormone+_HER2- Letrozole Novartis SubTotal 3. Inducing Angiogen- esis VEGF Signaling Bevacizumab VEGF HER2- Unknown as of 8/1 Sorafenib  VEGF All Capecitabine  Yale Cancer Center Apatanib (YN968D) VEGF All LSK BioPharma Pazopanib VEGF All Paclitaxel/ carboplatin Rutgers University 4. Resisting Cell Death IAP (Inhibit apoptosis proteins) LCL161 IAP All Paclitaxel Novartis 5. Enabling Replica- tive Immorality NOT IN TRIALS FOR MBC 6. Genome Instability and Mutation PARP Inhibitors Veliparib PARP BRCA+ Temozolomide vs. carboplatin/ paclitaxel AbbVie Veliparib PARP TripleNegative Doxorubicin National Cancer Institute/ Montiforie Medical Center Veliparib PARP All Paclitaxel/paraplatin chemotherapy National Cancer Institute/ University of Pittsburgh Active, not recruiting Veliparib PARP BRCA+ With/without carbo- platin National Cancer Institute Veliparib PARP HER2- Paclitaxel/paraplatin chemotherapy National Cancer Institute/ University of Pittsburgh Veliparib PARP Hormone+_HER2- Carboplatin National Cancer Institute Active, not recruiting Veliparib  PARP BRCA+ AbbVie Veliparib PARP All Radiation University of Michigan Com- prehensive Cancer Center Active, not recruiting Veliparib/cyclophospha- mide PARP BRCA+ With/without doxo- rubicin National Cancer Institute BMN 673 "PARP BRCA+ Various Chemo agents BioMarin " BRCA+ Various chem- otherapeutic agents BioMarin BioMarin BMN 673 "PARP BRCA+ NCI AZD2281 (Olaparib) PARP BRCA+ Carboplatin NCI " BRCA+ BioMarin With/without Carboplatin NCI Study Drug(s) Target Biomarkers/ Subtype Combination Sponsor